Advanced search
Start date

RGDfK-functionalized ultrasmall silica nanoparticles as treatment of glioblastoma under normoxic and hypoxic conditions

Grant number: 19/20268-4
Support Opportunities:Scholarships abroad - Research Internship - Post-doctor
Effective date (Start): December 01, 2019
Effective date (End): November 30, 2020
Field of knowledge:Physical Sciences and Mathematics - Physics - Condensed Matter Physics
Principal Investigator:Valtencir Zucolotto
Grantee:Bianca Martins Estevão
Supervisor: Luisa de Cola
Host Institution: Instituto de Física de São Carlos (IFSC). Universidade de São Paulo (USP). São Carlos , SP, Brazil
Research place: Université de Strasbourg, France  
Associated to the scholarship:17/22056-9 - Nanosystems containing proton "sponge"/gold nanoparticles for tumor hypoxia conditions, BP.PD


According to the World Health Organization, one of the most deadly diseases in the world is cancer. With over 100 types of cancer detected, this disease is constantly changing, making it difficult to choose of treatment. Some types of cancer are silent, and when diagnosed late they are in malignant progression and metastasis. Tumors in the advanced stage are highly vascularized, but unbalanced. In this case, the cells rapidly proliferate performing anaerobic respiration. As a consequence, a high concentration of lactic acid appears, leading to a decrease in the pH of the medium, known as tumor hypoxia. Based on this, much research has been done on how to reverse this tumor cell-modified metabolic process. In this context, drugs that block lactate output as a signaling agent and alternative therapies that do not cause side effects, such as NO therapy, are being recently explored. In addition, drug-associated vectorized nanoparticles are in what we know about the state of the art of nanomedicine, especially in overcoming the blood brain barrier when related to glioblastoma. In this context, this BEPE project aims to therapeutically apply ultra-small silica nanoparticles to glioma cancer cells under normoxia and hypoxia conditions. Si NPs will carry CHCA and N- [4-nitro-3- (trifluoromethyl)phenyl] propane-1,3-diamine (NOP) as the release blocker for extracellular lactate and photodon or NO, respectively; with further functionalization with cyclic peptide RGDfK for selective delivery. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Please report errors in scientific publications list using this form.